Additionally, the evERA breast cancer trial (NCT05306340) compares giredestrant plus everolimus with the physicians’ choice, endocrine therapy plus everolimus, in later than first-line settings of ER+ HER2− metastatic breast cancer. Here, ERBB2 is linked to breast carcinoma.